Tocilizumab for Hard-to-Treat Breast Inflammation
Treatments studied
Part of Skin, Women’s health & pregnancy clinical trials.
This trial tests tocilizumab, a medication that reduces inflammation, for granulomatous lobular mastitis (GLM)—a rare, persistent breast inflammation. If your GLM hasn't responded to steroid therapy or you can't tolerate steroids, this study may help reduce inflammation and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 20–50 years
- You have been diagnosed with non-lactational granulomatous lobular mastitis (no breastfeeding for at least 6 months) confirmed by biopsy
- Your condition is either steroid-resistant or you cannot tolerate steroids
- You are not pregnant and agree to use reliable birth control for at least 16 weeks after treatment
- You do not have active or recent serious infections (viral, bacterial, fungal, or TB)
- Your liver, kidney, and blood cell counts are within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different ways to treat granulomatous lobular mastitis (GLM), a type of breast inflammation that is not an infection. The goal is to find which treatment works best for people with this condition.
This study compares two common treatments—antibiotics and steroids—to see which works better for a rare breast inflammation condition called granulomatous lobular mastitis (GLM). It aims to find the most effective and safe option for women with this condition.
This trial tests a traditional Chinese herbal medicine (Sanyong Jiedu Granules) to treat non-lactational mastitis—a breast condition involving lumps and inflammation not related to breastfeeding. The study aims to see if this herbal treatment safely reduces these lumps.
This study is creating a registry (a database) for people with a rare inflammatory breast condition called granulomatous mastitis. It aims to learn more about the disease and how it affects people, without testing any new treatments.
This Phase 2 trial tests whether adding tocilizumab (a drug that targets inflammation signals) to standard chemotherapy helps people with triple-negative or ER-low metastatic or locally recurring breast cancer. It’s for adults who have had up to two prior treatments for metastatic disease and who can receive standard chemo.
This trial tests whether a steroid injection directly into the breast can help treat idiopathic granulomatous mastitis (IGM), a rare non-cancerous inflammatory breast condition. If you have been diagnosed with IGM, this study offers a potentially less invasive treatment option.
Hear when a new Granulomatous Mastitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.